Minimally Invasive Staging of Apparent Stage I Malignant Ovarian Germ Cell Tumors: Prevalence and Outcomes

被引:3
|
作者
Nasioudis, Dimitrios [1 ]
Minis, Evelyn [2 ]
Chapman-Davis, Eloise [2 ]
Frey, Melissa K. [2 ]
Caputo, Thomas A. [2 ]
Witkin, Steven S. [2 ]
Holcomb, Kevin [2 ]
机构
[1] Hosp Univ Penn, Dept Obstet & Gynecol, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Weill Cornell Med, Dept Obstet & Gynecol, New York, NY USA
关键词
Germ cell tumor; Laparoscopy; Ovary; MANAGEMENT;
D O I
10.1016/j.jmig.2018.05.021
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Study Objective: Evaluate the prevalence, trends, and outcomes of minimally invasive surgical (MIS) staging of malignant ovarian germ cell tumors (MOGCTs) apparently confined to the ovary. Design: Retrospective cohort study (Canadian Task Force classification II-2). Setting: Participating hospitals in the National Cancer Data Base. Patients: Women diagnosed between 2010 and 2014 with a MOGCT apparently confined to the ovary with information on the planned surgical approach. Interventions: Staging with MIS or laparotomy. Measurement and Main Results: A total of 918 patients were identified. MIS was planned for 294 patients (32%): a laparoscopic approach for 237 patients and a robotic-assisted approach for 57 patients. Rate of conversion to laparotomy was 11% (46 cases), 1.7% and 15.6% in the robotic and laparoscopy groups, respectively (p = .003). No difference in the use of MIS was noted based on year of diagnosis (p = .38). By multivariate analysis white race, higher level of education, and smaller tumor size were associated with the receipt of MIS. Patients in the MIS group were less likely to undergo lymph node dissection (39.6% vs 51.3%, p = .001) and omentectomy (18.7% vs 28.5%, p = .002). Hospital stay after surgery was shorter for patients who had MIS (median, 2 vs 3 days; p <.001). Unplanned 30-day readmission rate was also lower in the MIS group (1.4% vs 3.9%, p = .043). No difference in overall survival was noted between the 2 groups (p = .81). Conclusion: MIS for apparent early-stage MOGCTs was less comprehensive but associated with a decreased hospital stay and unplanned readmission rate. (C) 2018 AAGL. All rights reserved.
引用
收藏
页码:471 / 476
页数:6
相关论文
共 50 条
  • [21] FDG-PET in the staging of low stage malignant testicular germ cell tumors
    Bender, H
    Albers, P
    Yilmaz, H
    Schoeneich, G
    Ruhlmann, J
    Biersack, HJ
    Müller, SC
    JOURNAL OF UROLOGY, 1998, 159 (05): : 316 - 316
  • [22] Management of Malignant Ovarian Germ Cell Tumors
    Parkinson, Christine A.
    Hatcher, Helen M.
    Ajithkumar, Thankamma V.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2011, 66 (08) : 507 - 514
  • [23] Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors
    Weinberg, Lori E.
    Lurain, John R.
    Singh, Diljeet K.
    Schink, Julian C.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 285 - 289
  • [24] Laparoscopic staging for apparent stage I epithelial ovarian cancer
    Melamed, Alexander
    Keating, Nancy L.
    Clemmer, Joel T.
    Bregar, Amy J.
    Wright, Jason D.
    Boruta, David M.
    Schorge, John O.
    del Carmen, Marcela G.
    Rauh-Hain, J. Alejandro
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 216 (01)
  • [25] Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors
    Nasioudis, Dimitrios
    Chapman-Davis, Eloise
    Frey, Melissa K.
    Caputo, Thomas A.
    Witkin, Steven S.
    Holcomb, Kevin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (03) : 554 - 559
  • [26] Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors
    Nasioudis, D.
    Chapman-Davis, E.
    Frey, M. K.
    Caputo, T. A.
    Witkin, S. S.
    Holcomb, K. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 190 - 191
  • [27] Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer).
    Bergamini, Alice
    Giorda, Giorgio
    Ferrandina, Gabriella
    Cormio, Gennaro
    Lorusso, Domenica
    Cassani, Chiara
    Raspagliesi, Francesco
    Marinaccio, Marco
    Bertone, Elena
    Frigerio, Luigi
    Scarfone, Giovanna
    Perrone, Myriam
    Bocciolone, Luca
    Savarese, Antonella
    Pignata, Sandro
    Mangili, Giorgia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] UPDATE ON MALIGNANT OVARIAN GERM-CELL TUMORS
    GERSHENSON, DM
    CANCER, 1993, 71 (04) : 1581 - 1590
  • [29] The management of malignant nondysgerminomatous ovarian germ cell tumors
    Gadducci, A
    Cosio, S
    Muraca, S
    Genazzani, AR
    ANTICANCER RESEARCH, 2003, 23 (2C) : 1827 - 1836
  • [30] MANAGING MALIGNANT OVARIAN GERM-CELL TUMORS
    RUSTIN, GJS
    BRITISH MEDICAL JOURNAL, 1987, 295 (6603): : 869 - 870